R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures.

Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.

Dr. Peterson brings over 20 years of diverse research experience ranging from preclinical early compound discovery to post-marketing clinical study design. He has been the recipient of numerous academic research awards from the NIH and the National Multiple Sclerosis Society. Earlier in his career, Dr. Peterson held roles of increasing responsibility at Allergan and SkinMedica. Prior to joining Evolus, he served as Head of US Medical Affairs for SkinCeuticals, L’Oreal.